Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Con...
Guardado en:
Autores principales: | Yannuzzi NA, Freund KB |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae288 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
por: Chakraborty D, et al.
Publicado: (2021) -
Side Effects of Brolucizumab
por: Tahmineh Motevasseli, et al.
Publicado: (2021) -
Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
por: Andrea Montesel, et al.
Publicado: (2021) -
Management of neovascular age-related macular degeneration: Taiwan expert consensus
por: Ling Yeung, et al.
Publicado: (2021) -
Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
por: Balaratnasingam C, et al.
Publicado: (2015)